Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

New CRISPR System Targets Both DNA and RNA

Page View:

    With a staggering number of papers published in the past several years involving the characterization and use of the CRISPR/Cas9 gene editing system, it is surprising that researchers are still finding new features of the versatile molecular scissor enzyme.  Researchers from the Max Planck Institute for Infection Biology in Berlin, the Umeå University in Sweden and the Helmholtz Centre for Infection Research in Braunschweig have now discovered a feature of the CRISPR-associated protein Cpf1 that has previously not been observed in this family of enzymes: Cpf1 exhibits dual, RNA and DNA, cleavage activity.

    In the CRISPR/Cas9 system, the enzyme Cas9 cuts viral DNA at a location specified by an RNA molecule—the CRISPR RNA (crRNA)—in complex with another RNA, the so-called tracrRNA. This is the bacterial version of an immune system and helps put pathogens out of action.

In contrast to CRISPR/Cas9, Cpf1 can process the pre-crRNA on its own, and then using the processed RNA to target and cut DNAspecifically. Not requiring a host-derived RNase and the tracrRNA makes this the most minimalistic CRISPR immune system yet. The mechanism of combining two separate catalytic modalities in one allows for possible new avenues for sequence specific genome engineering, most importantly facilitation of targeting multiple sites at once or multiplexing.

    Previous work from the Max Planck team described a system that consists of two RNAs forming a duplex (tracrRNA and pre-crRNA), with tracrRNA maturing pre-crRNA to crRNA, in the presence of the protein Cas9. Moreover, the research group demonstrated that tracrRNA and crRNA together, either in the form of the duplex of two guide RNAs or a fused single guide RNA, are required to guide the Cas9 enzyme accurately to the matching target DNA sequence—outlining the molecular mechanisms of the primary CRISPR/Cas9 system.


    “Although the workings of CRISPR/Cas9 sound simple, the details of the mechanisms involved are rather subtle,” explained senior study author Emmanuelle Charpentier, Ph.D., director at the Max Planck Institute for Infection Biology and co-discoverer of CRISPR/Cas9’s role in genome editing.

    In this new study, the investigators showed that the immune defense mechanism of some bacteria a simpler in structure than CRISPR/Cas9. In addition to Cas9, these bacteria use the enzyme Cpf1 for cleaving foreign DNA. This resulted in identifying a dual nuclease role for Cpf1.

    “We demonstrate a novel mechanism in CRISPR–Cas immunity. We show that type V-A Cpf1 from Francisella novicida is a dual-nuclease that is unique to crRNA biogenesis and target DNA interference,” the authors wrote. “Cpf1 cleaves pre-crRNA upstream of a hairpin structure formed within the CRISPR repeats and thereby generates intermediate crRNAs that are processed further, leading to mature crRNAs. After recognition of a 5′-YTN-3′ protospacer adjacent motif on the non-target DNA strand and subsequent probing for an eight-nucleotide seed sequence, Cpf1, guided by the single mature repeat-spacer crRNA, introduces double-stranded breaks in the target DNA to generate a 5′ overhang.”

    The findings from this study were published recently in Nature in an article entitled “The CRISPR-Associated DNA-Cleaving Enzyme Cpf1 Also Processes Precursor CRISPR RNA.”

    Additionally, the scientists discovered that the CRISPR/Cpf1 system does require enzymes like RNase III and is not depending on the help of a tracrRNA molecule to reach its destination. Consequently, it is even simpler in structure than CRISPR/Cas9.

    “CRISPR/Cpf1 is a plug-and-play system with no additional component needed. In contrast, CRISPR/Cas9 needs in its natural setting an assistant to activate the system,” Dr. Charpentier stated.

    “If the CRISPR/Cpf1 system provides any tangible added value over the CRISPR/Cas9 system when it comes to eukaryotic gene editing remains to be elucidated,” Dr. Charpentier added. “However, it is stunning to see how evolution has succeeded to yield a dramatically minimalistic but effective immune system to fight invading viruses. There may be more such systems to be found in nature in the future, the search for them is already in full swing.”

Relevant newsRelevant news